Our top pick for
Cushman & Wakefield plc is a real estate services business based in the US. Cushman-and-Wakefield shares (CWK) are listed on the NYSE and all prices are listed in US Dollars. Cushman-and-Wakefield employs 53,000 staff and has a trailing 12-month revenue of around USD$8.2 billion.
|52-week range||USD$6.84 - USD$19.45|
|50-day moving average||USD$15.0691|
|200-day moving average||USD$13.4541|
|Wall St. target price||USD$16.34|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.001|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Cushman-and-Wakefield stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cushman-and-Wakefield's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cushman-and-Wakefield's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10090x. In other words, Cushman-and-Wakefield shares trade at around 10090x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Cushman-and-Wakefield's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$317.5 million.
The EBITDA is a measure of a Cushman-and-Wakefield's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$8.2 billion|
|Operating margin TTM||0.39%|
|Gross profit TTM||USD$1.8 billion|
|Return on assets TTM||0.29%|
|Return on equity TTM||-16.67%|
|Market capitalisation||USD$3.8 billion|
TTM: trailing 12 months
There are currently 6.8 million Cushman-and-Wakefield shares held short by investors – that's known as Cushman-and-Wakefield's "short interest". This figure is 4.8% up from 6.5 million last month.
There are a few different ways that this level of interest in shorting Cushman-and-Wakefield shares can be evaluated.
Cushman-and-Wakefield's "short interest ratio" (SIR) is the quantity of Cushman-and-Wakefield shares currently shorted divided by the average quantity of Cushman-and-Wakefield shares traded daily (recently around 662220.41015625). Cushman-and-Wakefield's SIR currently stands at 10.24. In other words for every 100,000 Cushman-and-Wakefield shares traded daily on the market, roughly 10240 shares are currently held short.
However Cushman-and-Wakefield's short interest can also be evaluated against the total number of Cushman-and-Wakefield shares, or, against the total number of tradable Cushman-and-Wakefield shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cushman-and-Wakefield's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Cushman-and-Wakefield shares in existence, roughly 30 shares are currently held short) or 0.0541% of the tradable shares (for every 100,000 tradable Cushman-and-Wakefield shares, roughly 54 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Cushman-and-Wakefield.
Find out more about how you can short Cushman-and-Wakefield stock.
We're not expecting Cushman-and-Wakefield to pay a dividend over the next 12 months.
Over the last 12 months, Cushman-and-Wakefield's shares have ranged in value from as little as $6.84 up to $19.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Cushman-and-Wakefield's is 1.5227. This would suggest that Cushman-and-Wakefield's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cushman & Wakefield plc provides commercial real estate services under the Cushman & Wakefield brand in the Americas, the Asia Pacific, Europe, the Middle East, and Africa. The company's operating segments include the Americas; Europe, Middle East and Africa; and Asia Pacific. It offers integrated facilities management, project and development, portfolio administration, transaction management, and strategic consulting services; property management services, including client accounting, engineering and operations, lease compliance administration, project and development, and sustainability services; and janitorial, maintenance, critical environment management, landscaping, and office services. The company also provides owner representation and tenant representation leasing services; capital market services, such as investment sales and equity, and debt and structured financing for real estate purchase and sales transactions; and appraisal management, investment management, valuation advisory, portfolio advisory, diligence advisory, dispute analysis and litigation support, financial reporting, and property and/or portfolio valuation services on real estate debt and equity decisions. Cushman & Wakefield has a strategic partnership with Vanke Service. It serves real estate owners and occupiers. Cushman & Wakefield plc was founded in 1784 and is headquartered in Chicago, Illinois.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.